List view / Grid view
15 January 2018 | By Richard M Johnson - Parenteral Drug Association (PDA)
The pharmaceutical industry has seen a lot of change in the last 21 years. In 1996 the internet was relatively new and limited to computer access, mobile devices were bulky and expensive, and security concerns were primarily physical. Similarly, a lot has changed with regards to business, manufacturing and regulation,…
12 January 2018 | By Mark Quick - Recipharm
Mark Quick, Executive Vice-president, Corporate Development at Recipharm, explains how his company has set about becoming a best-in-class provider of contract development and manufacturing solutions to the pharmaceutical industry.
12 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Ocrelizumab provides a new treatment option for adults with active relapsing forms of multiple sclerosis...
12 January 2018 | By Will Downie - Catalent
Catalent believes it is essential to share knowledge and experience to improve understanding of drug formulation and delivery challenges and contribute jointly to finding solutions. Will Downie, Senior Vice President, Global Sales and Marketing at Catalent, explains how his company makes a success of this strategy...
11 January 2018 | By Andreas Weiler, Fatma Senkesen - Lonza
Andreas Weiler, Business Unit Head for Emerging Technologies, and Fatma Senkesen, Marketing Intelligence Associate Director, at Lonza, explain how their company has kept in step with industry developments.
11 January 2018 | By William S Marth - AMRI
Since 2014, AMRI has significantly expanded its service and product range through several acquisitions. Today, it has more than 3,100 employees at 27 locations in the US, UK, Europe and Asia, and it continues to seek new opportunities in areas of complex science. William S Marth, President and Chief Executive…
10 January 2018 | By John E Bournas - ISPE
Twenty five years ago, the European Community took a major step toward political and economic union by adopting the Treaty of Maastricht. The Treaty created the European Union (EU), paving the way for closer economic ties within the Union through the free movement of goods between member states. This opening…
10 January 2018 | By Michel Pettigrew - Ferring Pharmaceuticals
Michel Pettigrew, President of the Executive Board and Chief Operating Officer at Ferring Pharmaceuticals, explains how his company’s decentralised model and focus on entrepreneurialism is helping it to deliver personalised medicine.
10 January 2018 | By Watson-Marlow Fluid Technology Group
New from Watson-Marlow Fluid Technology Group (WMFTG) is the Flexicon PF7 peristaltic tabletop aseptic liquid filling machine optimised for operation in GMP regulated industries such as biotechnology, pharmaceutical and diagnostics...
9 January 2018 | By Dr Masashi Miyamoto - Kyowa Hakko Kirin
Dr Masashi Miyamoto, Director of the Board, Managing Executive Officer, Director of Corporate Strategy & Planning Department at Kyowa Hakko Kirin, explains his company’s five-year mid-term plan (2016-2020) to become a global specialty pharmaceutical company, and other significant initiatives...
9 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Phase 3 clinical program for upadacitinib in atopic dermatitis, the most common type of eczema, is planned to begin in the first half of 2018...
9 January 2018 | By Jacek Glinka - Mylan
Mylan works with industry associations and key stakeholders to improve sustainability of the healthcare system. Jacek Glinka, President, Mylan Europe, explains how...
8 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The EMA has accepted the Marketing Authorization Application for romosozumab in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture...
8 January 2018 | By Allan Hillgrove - Boehringer Ingelheim
Allan Hillgrove, Member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit at Boehringer Ingelheim, tells EPR about some of his company’s achievements that he is most proud of, and describes how it will face the digital challenge...
8 January 2018 | By Marc Princen - Allergan
Marc Princen, Executive Vice President and President Allergan International, explains how Allergan’s novel ethos and innovative approach makes it stand out from the crowd...
Send this to a friend
Follow: